Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye

F. S. Mah, Terrence O'Brien, T. Kim, G. Torkildsen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Olopatadine hydrochloride 0.2% (Patadayt, Alcon, Fort Worth, USA) is a topical ocular anti-allergic agent that has shown high rates of efficacy in treating ocular itching, the primary symptom of allergic conjunctivitis, and allows for once-daily dosing. Since some patients suffer from signs or symptoms of dry eye in addition to ocular allergy, this study was designed to evaluate the safety of olopatadine 0.2% in a population of patients with both allergic conjunctivitis and dry eye. Methods: This was a single-center, 3-visit, double-masked, randomized study. Fifty-two patients diagnosed with ocular allergy and mild-to-moderate dry eye were evaluated. After a run-in period, patients were randomized to receive either olopatadine hydrochloride 0.2% or a tear saline, and self-dosed once-daily for 1 week. Outcome measures included tear film break-up time, corneal and conjunctival staining, tear volume and flow as measured by fluorophotometry, Schirmer's test, injection, and symptom evaluations. Results: No significant differences between the treatment groups were observed (p > 0.05). No serious adverse events occurred during the trial. Variability in the presentation of dry eye can hinder the observation of treatment effects. Although the study design facilitated the comparison of olopatadine 0.2% against an agent that was certain to not exacerbate dry eye, future comparison of olopatadine 0.2% against other agents in its drug class would provide useful information about relative drug tolerabilities. Conclusion: As there were no significant changes in the signs and symptoms of dry eye, olopatadine hydrochloride 0.2% is safe to use in ocular allergy patients with mild-to-moderate dry eye.

Original languageEnglish
Pages (from-to)441-447
Number of pages7
JournalCurrent Medical Research and Opinion
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Allergic Conjunctivitis
Ophthalmic Solutions
Tears
Hypersensitivity
Signs and Symptoms
Olopatadine Hydrochloride
Fluorophotometry
Anti-Allergic Agents
Symptom Assessment
Pruritus
Double-Blind Method
Pharmaceutical Preparations

Keywords

  • Allergic conjunctivitis
  • Dry eye
  • Ocular surface disease
  • Olopatadine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. / Mah, F. S.; O'Brien, Terrence; Kim, T.; Torkildsen, G.

In: Current Medical Research and Opinion, Vol. 24, No. 2, 01.02.2008, p. 441-447.

Research output: Contribution to journalArticle

@article{f55fb967b8db4e108e0e17ceee8fd982,
title = "Evaluation of the effects of olopatadine ophthalmic solution, 0.2{\%} on the ocular surface of patients with allergic conjunctivitis and dry eye",
abstract = "Purpose: Olopatadine hydrochloride 0.2{\%} (Patadayt, Alcon, Fort Worth, USA) is a topical ocular anti-allergic agent that has shown high rates of efficacy in treating ocular itching, the primary symptom of allergic conjunctivitis, and allows for once-daily dosing. Since some patients suffer from signs or symptoms of dry eye in addition to ocular allergy, this study was designed to evaluate the safety of olopatadine 0.2{\%} in a population of patients with both allergic conjunctivitis and dry eye. Methods: This was a single-center, 3-visit, double-masked, randomized study. Fifty-two patients diagnosed with ocular allergy and mild-to-moderate dry eye were evaluated. After a run-in period, patients were randomized to receive either olopatadine hydrochloride 0.2{\%} or a tear saline, and self-dosed once-daily for 1 week. Outcome measures included tear film break-up time, corneal and conjunctival staining, tear volume and flow as measured by fluorophotometry, Schirmer's test, injection, and symptom evaluations. Results: No significant differences between the treatment groups were observed (p > 0.05). No serious adverse events occurred during the trial. Variability in the presentation of dry eye can hinder the observation of treatment effects. Although the study design facilitated the comparison of olopatadine 0.2{\%} against an agent that was certain to not exacerbate dry eye, future comparison of olopatadine 0.2{\%} against other agents in its drug class would provide useful information about relative drug tolerabilities. Conclusion: As there were no significant changes in the signs and symptoms of dry eye, olopatadine hydrochloride 0.2{\%} is safe to use in ocular allergy patients with mild-to-moderate dry eye.",
keywords = "Allergic conjunctivitis, Dry eye, Ocular surface disease, Olopatadine",
author = "Mah, {F. S.} and Terrence O'Brien and T. Kim and G. Torkildsen",
year = "2008",
month = "2",
day = "1",
doi = "10.1185/030079908X261078",
language = "English",
volume = "24",
pages = "441--447",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye

AU - Mah, F. S.

AU - O'Brien, Terrence

AU - Kim, T.

AU - Torkildsen, G.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: Olopatadine hydrochloride 0.2% (Patadayt, Alcon, Fort Worth, USA) is a topical ocular anti-allergic agent that has shown high rates of efficacy in treating ocular itching, the primary symptom of allergic conjunctivitis, and allows for once-daily dosing. Since some patients suffer from signs or symptoms of dry eye in addition to ocular allergy, this study was designed to evaluate the safety of olopatadine 0.2% in a population of patients with both allergic conjunctivitis and dry eye. Methods: This was a single-center, 3-visit, double-masked, randomized study. Fifty-two patients diagnosed with ocular allergy and mild-to-moderate dry eye were evaluated. After a run-in period, patients were randomized to receive either olopatadine hydrochloride 0.2% or a tear saline, and self-dosed once-daily for 1 week. Outcome measures included tear film break-up time, corneal and conjunctival staining, tear volume and flow as measured by fluorophotometry, Schirmer's test, injection, and symptom evaluations. Results: No significant differences between the treatment groups were observed (p > 0.05). No serious adverse events occurred during the trial. Variability in the presentation of dry eye can hinder the observation of treatment effects. Although the study design facilitated the comparison of olopatadine 0.2% against an agent that was certain to not exacerbate dry eye, future comparison of olopatadine 0.2% against other agents in its drug class would provide useful information about relative drug tolerabilities. Conclusion: As there were no significant changes in the signs and symptoms of dry eye, olopatadine hydrochloride 0.2% is safe to use in ocular allergy patients with mild-to-moderate dry eye.

AB - Purpose: Olopatadine hydrochloride 0.2% (Patadayt, Alcon, Fort Worth, USA) is a topical ocular anti-allergic agent that has shown high rates of efficacy in treating ocular itching, the primary symptom of allergic conjunctivitis, and allows for once-daily dosing. Since some patients suffer from signs or symptoms of dry eye in addition to ocular allergy, this study was designed to evaluate the safety of olopatadine 0.2% in a population of patients with both allergic conjunctivitis and dry eye. Methods: This was a single-center, 3-visit, double-masked, randomized study. Fifty-two patients diagnosed with ocular allergy and mild-to-moderate dry eye were evaluated. After a run-in period, patients were randomized to receive either olopatadine hydrochloride 0.2% or a tear saline, and self-dosed once-daily for 1 week. Outcome measures included tear film break-up time, corneal and conjunctival staining, tear volume and flow as measured by fluorophotometry, Schirmer's test, injection, and symptom evaluations. Results: No significant differences between the treatment groups were observed (p > 0.05). No serious adverse events occurred during the trial. Variability in the presentation of dry eye can hinder the observation of treatment effects. Although the study design facilitated the comparison of olopatadine 0.2% against an agent that was certain to not exacerbate dry eye, future comparison of olopatadine 0.2% against other agents in its drug class would provide useful information about relative drug tolerabilities. Conclusion: As there were no significant changes in the signs and symptoms of dry eye, olopatadine hydrochloride 0.2% is safe to use in ocular allergy patients with mild-to-moderate dry eye.

KW - Allergic conjunctivitis

KW - Dry eye

KW - Ocular surface disease

KW - Olopatadine

UR - http://www.scopus.com/inward/record.url?scp=39749169725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749169725&partnerID=8YFLogxK

U2 - 10.1185/030079908X261078

DO - 10.1185/030079908X261078

M3 - Article

C2 - 18167176

AN - SCOPUS:39749169725

VL - 24

SP - 441

EP - 447

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -